Business Context and Reporting Period
KALA BIO, Inc. (Nasdaq: KALA) filed a Current Report on Form 8-K on May 7, 2026. The filing announces the implementation of a 1-for-50 reverse stock split of its common stock, effective May 8, 2026, following stockholder approval at the 2025 annual meeting held on January 30, 2026.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
- Share Count Reduction: The number of outstanding common shares will decrease from 929,491,578 to approximately 18,589,832 shares.
- Authorized Shares: The total number of authorized shares remains unchanged at 1,500,000,000.
- Trading Adjustments: The stock will begin trading on a split-adjusted basis on May 11, 2026, under the symbol "KALA" with a new CUSIP number (483119301).
- Fractional Shares: No fractional shares will be issued; holders entitled to fractional shares will receive cash payments based on the closing price on May 7, 2026.
Guidance, Outlook, and Management Commentary
The Board of Directors determined the 1-for-50 ratio within the previously approved range of 1-for-2 to 1-for-100. Proportionate adjustments will be made to the exercise prices and share counts for outstanding equity awards under the Company's 2009 and 2017 Equity Incentive Plans and the 2017 Employee Stock Purchase Plan. The number of shares reserved for issuance under these plans will also be proportionately reduced. The filing references a definitive proxy statement filed on December 30, 2026, for further details.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (May 8, 2026) and the first day of adjusted trading (May 11, 2026).
- Confirm the new CUSIP number (483119301) for trading and settlement purposes.
- Review the treatment of fractional shares and the specific closing price used for cash-in-lieu calculations.
- Check the impact of the split on outstanding options, warrants, and other equity awards held by employees or investors.
- Examine the Certificate of Amendment (Exhibit 3.1) for any additional legal stipulations regarding the capital structure.